Mink Therapeutics Inc (INKT) Stock Price, Quote & News

Company Profile

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilima...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 994 8250

Website: minktherapeutics.com

Address:

149 Fifth Avenue, Suite 500, New York, United States

enkemm Jul. 24 at 12:41 AM

$INKT Hey...anyone know anything about INAB. Apparrently, they are using T Cells to treat glioblastoma (brain cancer), and the T cells can cross the blood/brain barrier unlike most other forms of treatment like chemo. Prelimenary results look a bit promising...wouldn't that be something...even if just an extra 6 to 12 months of living.

0 · Reply

enkemm Jul. 24 at 12:31 AM

$INKT Patience is the key for investors in tiny low volume speculative stocks like INKT. The day traders and shorts manipulate the stock within a 1 to 2 dollar range endlessly. However, Preliminary data from the C-1300-02 Phase 2 study evaluating agenT-797 for acute respiratory distress syndrome (ARDS) at the First Lviv Territorial Medical Union in Ukraine and U.S. sites are expected in the second half of 2026. Holy Mackrel...if that data good we could move to 25 to 35 dollars a share and hold there just long enough to see a 2 or 3 to 1 stock split. Ahhhhhhhh...pipe dreams...but pleasant to reflect upon😀

0 · Reply

Overcrumb Jul. 23 at 2:54 PM

$INKT why is there a delayed quote for INKT?

1 · Reply

enkemm Jul. 23 at 1:08 PM

$INKT There are only 112,500 short shares outstanding, and total shares issued are about 5,000,000. 10,000,000 available to borrow appears to be a mistake....

0 · Reply

OrientBeach Jul. 22 at 10:38 PM

$INKT 10.0M short shares available to borrow? Strange https://fintel.io/ss/us/inkt

0 · Reply

OrientBeach Jul. 21 at 3:41 PM

$INKT . . . so volatile on such low volume these days

1 · Reply

OrientBeach Jul. 18 at 12:01 PM

$INKT The Phase 2 trial (ClinicalTrials.gov ID NCT07492888) evaluating ImmunityBio's Anktiva (nogapendekin alfa inbakicept) and MiNK Therapeutics' off-the-shelf iNKT cell therapy for critically ill adults with pneumonia, sepsis, and ARDS was withdrawn in May 2026

1 · Reply

svertical1 Jul. 17 at 7:07 PM

$IBRX $INKT @Atomickb No, just that both IBRX & INKT are partnered in Critically ill 30 Patient Pneumonia/Sepsis Trial. These are patients who will likely die without miraculous intervention. I don’t think I’ve ever seen a Trial with no downside, and unlimited upside (Pneumonia/Sepsis market is massive), if lives are indeed saved. But what’s new, another important Trial overlooked by analysts.

1 · Reply

svertical1 Jul. 17 at 3:41 PM

$IBRX $INKT Yes, I know, beyond speculation…. https://people.com/rudy-giuliani-81-is-out-of-the-icu-after-receiving-last-rites-11969018

0 · Reply

svertical1 Jul. 17 at 3:38 PM

$IBRX $INKT Yeah- for those who know how to interpret Trump speak only…. https://en.newsner.com/news/donald-trump-says-new-drug-has-brought-people-back-to-life-in-bizarre-announcement/ ‘We had a person given the last rites, gone, the kids are crying and everything, and started them on this drug. And the person became better. It works,” Trump said’ Giuliani- Pneumonia/Sepsis Trial?? Regardless, 30 Patient Anktiva/NK Trial- Nov 2026 Completion. Huge Call Option to own IBRX & INKT. Pneumonia/Sepsis TAM larger than cancer.

3 · Reply

MiNK Therapeutics Transcript: AGM 2026

Jun 3, 2026, 4:30 PM EDT - 7 weeks ago

MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting

2026-05-28T14:12:03.000Z - 2 months ago

MiNK Therapeutics doses first patient in agenT-797 trial

May 28, 2026, 9:04 AM EDT - 2 months ago

MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness

2026-05-20T15:15:48.000Z - 2 months ago

MiNK Therapeutics reports new data on agenT-797 at ATS 2026

May 20, 2026, 11:07 AM EDT - 2 months ago

MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications

May 15, 2026, 8:30 AM EDT - 2 months ago

MiNK Therapeutics Earnings Call Transcript: Q1 2026

May 15, 2026, 8:30 AM EDT - 2 months ago

MiNK Therapeutics Earnings release: Q1 2026

May 15, 2026, 8:30 AM EDT - 2 months ago

MiNK Therapeutics Quarterly report: Q1 2026

May 15, 2026, 7:30 AM EDT - 2 months ago

MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation

IBRX

2026-05-14T17:31:11.000Z - 2 months ago

MiNK Therapeutics initiates agenT-797 clinical trial

May 14, 2026, 7:30 AM EDT - 2 months ago

MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness

May 12, 2026, 7:35 AM EDT - 2 months ago

MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026

May 8, 2026, 4:30 PM EDT - 2 months ago

MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs

Apr 30, 2026, 8:00 AM EDT - 3 months ago

MiNK Therapeutics Proxy statement: Proxy filing

2026-04-20T17:05:20.000Z - 3 months ago

MiNK Therapeutics management to meet virtually with B. Riley

$MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026$

Apr 3, 2026, 7:30 AM EDT - 3 months ago

MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026

Apr 1, 2026, 7:30 AM EDT - 4 months ago

MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference

Mar 31, 2026, 8:30 AM EDT - 4 months ago

MiNK Therapeutics Earnings Call Transcript: Q4 2025

Mar 31, 2026, 8:30 AM EDT - 4 months ago

MiNK Therapeutics Annual report: Q4 2025

Mar 31, 2026, 8:30 AM EDT - 4 months ago

MiNK Therapeutics Earnings release: Q4 2025

Mar 31, 2026, 7:30 AM EDT - 4 months ago

MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum

Mar 17, 2026, 7:30 AM EDT - 4 months ago

MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs

2026-03-11T14:11:00.000Z - 4 months ago

3 Penny Stocks to Watch Now, 3/11/26

ATPC LGVN

2026-03-10T12:33:59.000Z - 4 months ago

Why Is MiNK Therapeutics Stock (INKT) Up Today?

2026-03-10T09:40:45.000Z - 4 months ago

MiNK Therapeutics announces strategic collaboration with C-Further

Mar 10, 2026, 5:30 AM EDT - 4 months ago

MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers

2026-02-04T10:25:19.000Z - 6 months ago

MiNK Therapeutics announces new invariant natural killer T cells data

Feb 3, 2026, 9:30 PM EST - 6 months ago

MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia

2026-01-08T17:10:24.000Z - 7 months ago

MiNK, University of Wisconsin-Madison announce Phase 1 agenT-797 trial

Jan 8, 2026, 12:00 PM EST - 7 months ago

MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease

Dec 10, 2025, 7:00 AM EST - 8 months ago

MiNK Therapeutics Registration statement: Registration Filing

2025-11-20T16:45:18.000Z - 8 months ago

MiNK Therapeutics announces publication of new preclinical data for MiNK-215

Nov 20, 2025, 11:42 AM EST - 8 months ago

MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors

Nov 14, 2025, 8:30 AM EST - 8 months ago

MiNK Therapeutics Earnings Call Transcript: Q3 2025

Nov 14, 2025, 8:30 AM EST - 8 months ago

MiNK Therapeutics Quarterly report: Q3 2025

Nov 14, 2025, 8:30 AM EST - 8 months ago

MiNK Therapeutics Earnings release: Q3 2025

2025-11-14T12:35:56.000Z - 8 months ago

MiNK Therapeutics reports Q3 EPS (65c) vs (46c) last year

2025-11-07T22:00:18.000Z - 9 months ago

MiNK Therapeutics files $150M mixed securities shelf

2025-11-07T14:05:54.000Z - 9 months ago

MiNK Therapeutics reports updated clinical results on agenT-797

$MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025$

Nov 7, 2025, 9:00 AM EST - 9 months ago

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

Nov 7, 2025, 7:00 AM EST - 9 months ago

MiNK Therapeutics Registration statement: Registration Filing

2025-09-29T11:45:50.000Z - 10 months ago

MiNK Therapeutics appoints John Holcomb to board of directors

Sep 29, 2025, 7:30 AM EDT - 10 months ago

MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors

Sep 25, 2025, 7:30 AM EDT - 10 months ago

MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA

2025-09-18T11:40:33.000Z - 11 months ago

MiNK Therapeutics appoints Hammond as Head of Inflammatory, Pulmonary Diseases

Sep 18, 2025, 7:30 AM EDT - 11 months ago

MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development

2025-08-15T10:10:11.000Z - 1 year ago

MiNK Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

Aug 14, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings Call Transcript: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings release: Q2 2025

2025-08-14T11:40:29.000Z - 1 year ago

MiNK Therapeutics reports Q2 EPS ($1.06) vs (73c) last year

Aug 14, 2025, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results

Jul 31, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

2025-07-15T14:30:12.000Z - 1 year ago

H.C. Wainwright downgrades MiNK Therapeutics after 400% rally

Jul 15, 2025, 8:21 AM EDT - 1 year ago

MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy

Jun 10, 2025, 1:33 PM EDT - 1 year ago

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

Jun 2, 2025, 9:29 AM EDT - 1 year ago

MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients

May 15, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings Call Transcript: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Quarterly report: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings release: Q1 2025

May 15, 2025, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress

Apr 30, 2025, 8:00 AM EDT - 1 year ago

MiNK Therapeutics Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

MiNK Therapeutics Proxy statement: Proxy Filing

Mar 18, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings Call Transcript: Q4 2024

Mar 18, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Annual report: Q4 2024

Mar 18, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings release: Q4 2024

Mar 18, 2025, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

Mar 4, 2025, 7:30 AM EST - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Feb 24, 2025, 8:30 AM EST - 1 year ago

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting

Feb 12, 2025, 1:00 PM EST - 1 year ago

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

Jan 23, 2025, 2:13 PM EST - 1 year ago

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI

Dec 20, 2024, 7:00 AM EST - 1 year ago

MiNK Therapeutics Proxy statement: Proxy Filing

Dec 18, 2024, 9:45 AM EST - 1 year ago

MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting

Dec 6, 2024, 7:00 AM EST - 1 year ago

MiNK Therapeutics Proxy statement: Proxy Filing

Nov 14, 2024, 8:30 AM EST - 1 year ago

MiNK Therapeutics Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

MiNK Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

MiNK Therapeutics Earnings release: Q3 2024

Nov 11, 2024, 7:30 AM EST - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

Nov 7, 2024, 10:00 AM EST - 1 year ago

MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

Oct 31, 2024, 9:15 AM EDT - 1 year ago

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

Oct 8, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors

Oct 4, 2024, 9:10 AM EDT - 1 year ago

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024

Sep 9, 2024, 7:00 AM EDT - 2 years ago

MiNK Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 3, 2024, 7:30 AM EDT - 2 years ago

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

Aug 13, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings Call Transcript: Q2 2024

Aug 13, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Quarterly report: Q2 2024

Aug 13, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings release: Q2 2024

Aug 13, 2024, 8:00 AM EDT - 2 years ago

MiNK Therapeutics Registration statement: Registration Filing

Aug 13, 2024, 7:00 AM EDT - 2 years ago

MiNK Reports Second Quarter 2024 Results and Business Update

Aug 1, 2024, 7:30 AM EDT - 2 years ago

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

Jul 31, 2024, 7:30 AM EDT - 2 years ago

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

May 22, 2024, 7:30 AM EDT - 2 years ago

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

May 14, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings Call Transcript: Q1 2024

May 14, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Quarterly report: Q1 2024

May 14, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings release: Q1 2024

May 14, 2024, 7:30 AM EDT - 2 years ago

MiNK Reports First Quarter 2024 Results

May 13, 2024, 7:30 AM EDT - 2 years ago

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

Apr 30, 2024, 7:30 AM EDT - 2 years ago

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

Apr 29, 2024, 8:00 AM EDT - 2 years ago

MiNK Therapeutics Proxy statement: Proxy Filing

Apr 8, 2024, 12:00 PM EDT - 2 years ago

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

Mar 21, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings Call Transcript: Q4 2023

Mar 21, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Annual report: Q4 2023

Mar 21, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings release: Q4 2023

Mar 21, 2024, 7:00 AM EDT - 2 years ago

MiNK Reports Fourth Quarter and Year-End 2023 Results

Mar 7, 2024, 7:30 AM EST - 2 years ago

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

Mar 6, 2024, 8:30 AM EST - 2 years ago

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

$MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene$

Jan 30, 2024, 8:00 AM EST - 2 years ago

MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

Dec 20, 2023, 7:30 AM EST - 2 years ago

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

enkemm Jul. 24 at 12:41 AM

0 · Reply

enkemm Jul. 24 at 12:31 AM

0 · Reply

Overcrumb Jul. 23 at 2:54 PM

$INKT why is there a delayed quote for INKT?

1 · Reply

enkemm Jul. 23 at 1:08 PM

$INKT There are only 112,500 short shares outstanding, and total shares issued are about 5,000,000. 10,000,000 available to borrow appears to be a mistake....

0 · Reply

OrientBeach Jul. 22 at 10:38 PM

$INKT 10.0M short shares available to borrow? Strange https://fintel.io/ss/us/inkt

0 · Reply

OrientBeach Jul. 21 at 3:41 PM

$INKT . . . so volatile on such low volume these days

1 · Reply

OrientBeach Jul. 18 at 12:01 PM

1 · Reply

svertical1 Jul. 17 at 7:07 PM

1 · Reply

svertical1 Jul. 17 at 3:41 PM

$IBRX $INKT Yes, I know, beyond speculation…. https://people.com/rudy-giuliani-81-is-out-of-the-icu-after-receiving-last-rites-11969018

0 · Reply

svertical1 Jul. 17 at 3:38 PM

3 · Reply

Spartrap Jul. 17 at 11:20 AM

$INKT since May 14, they have probably wrapped up the run-in phase and should be about to start the RCT portion https://clinicaltrials.gov/study/NCT07615010

1 · Reply

Spartrap Jul. 16 at 10:59 PM

$INKT TB to the exciting P1 in ARDS that motivated the currently running P2: "Signals of associated survival and prevention of secondary infections were evident, including >80% reduction numerically in pneumonia at dose cohort 3 (15%) compared to combined numbers of cohorts 1 and 2 (71%) (Supplementary Table 2). Of the 20 patients treated in the context of the main trial, 14 (70%) survived (Supplementary Fig. 3A). Survival for the 5 individuals receiving mechanical ventilation plus VV-ECMO (4 study patients, 1 EUA patient) measured 80% (4/5 alive) at 30 days and 60% (3/5 alive) at 6 months " https://www.nature.com/articles/s41467-024-44905-z#MOESM1

0 · Reply

Biotechguy21 Jul. 15 at 7:22 PM

$AGEN $INKT is another pos.

0 · Reply

Biotechguy21 Jul. 14 at 8:34 PM

$AGEN same ceo of 30 years. now he is cfo and his son is a big part of the game. Jenny does the same atm games at $INKT and both companies are failing shs week by week. epic money machine 😂😂😂😂

0 · Reply

Dancady1 Jul. 13 at 10:15 PM

$INKT nom num nom

0 · Reply

Biotechguy21 Jul. 13 at 7:09 PM

$AGEN $INKT remember how fast these pos companies atm a sp to death. Facts and stay tuned 🤡😂🤡😂🤡

0 · Reply

Spartrap Jul. 13 at 2:39 PM

$INKT AGEN's major runway extension will more than probably benefit INKT. Also nice to see those guys that work for both companies know how to setup a deal and execute. I plan to buy more in the coming months before ARDS results

1 · Reply

pedmac2000 Jul. 10 at 1:49 PM

$AGEN $INKT $IBRX Probably good to keep an eye on INKT. I think ImmunityBio’s pneumonia/sepsis Trial is combo’d with INKT’s. 30 Patients, complete by Nov 2026. Was Giuliani in Trial? Trump’s statement about a friend who was given Last Rites with family crying, and then a few days later was out of the hospital?

1 · Reply

svertical1 Jul. 10 at 7:41 AM

$INKT $IBRX Probably good to keep an eye on INKT. I think ImmunityBio’s pneumonia/sepsis Trial is combo’d with INKT’s. 30 Patients, complete by Nov 2026. Was Giuliani in Trial? Trump’s statement about a friend who was given Last Rites with family crying, and then a few days later was out of the hospital?

1 · Reply

weichsel1 Jul. 9 at 1:51 PM

$INKT "Preliminary data are expected in the second half of 2026" - The C-1300-02 trial is a randomized Phase 2 study evaluating agenT-797 plus standard of care compared with placebo plus standard of care in adults with acute lung injury and critical illness, including moderate to severe acute hypoxemic respiratory failure. https://investor.minktherapeutics.com/news-releases/news-release-details/mink-therapeutics-announces-first-patient-dosed-randomized-phase

0 · Reply

Dancady1 Jul. 7 at 1:40 PM

$INKT no news for a while now…. Maybe some positive news with the patient in Ukraine being dosed a month ago

0 · Reply

OrientBeach Jul. 4 at 5:24 PM

$INKT Just to make a correction. Everglade is a solicitation agent for BARDA and NOT the name of BARDA’s ARDS program

0 · Reply

Market Cap	51.02M
Revenue (ttm)	0.00
Net Income (ttm)	-12.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	5,900
Avg Vol	30,380
Day's Range	N/A - N/A
Shares Out	4.98M
Stochastic %K	11%
Beta	0.47
Analysts	Strong Sell
Price Target	$39.00